Citius Oncology reports early LYMPHIR launch momentum with 83% of target accounts in formulary review

Citius Pharmaceuticals, Inc.

83% of target accounts have added or are actively progressing LYMPHIR through formulary review.
~135 health plans, covering ~80% of covered lives, secured; no reimbursement denials reported.
Repeat orders from early accounts; initial penetration into community infusion centers underway.
Investigator-sponsored studies: positive topline data in DLBCL at ASTCT 2026; Phase I combo with pembrolizumab completed.
International expansion underway via distribution agreements in Europe and Middle East.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.